icon Loading...

Revolutionizing Myocardial Infarction Management

Our mission is to provide patients with a faster alternative for management of suspected myocardial infarction (MI).


About OtiTopic

OtiTopic, Inc., founded in 2012, is a late-stage pharmaceutical company, with a track record of success in product drug delivery and drug device development. OtiTopic has changed the route of administration of a reference listed drug (RLD) and is on track to file a 505(b)(2) NDA for sale and marketing in the US.


See how we make a difference

Management of Suspected Heart Attack

A myocardial infarction (MI), commonly known as a heart attack, occurs every 40 seconds in the US. OtiTopic is committed to the development of a rapid therapy for the treatment of MI. OtiTopic has developed a dry powder inhalation treatment for MI that enters the bloodstream in less than two minutes.

Myocardial infarction occurs when an interruption in blood supply causes heart cell death from lack of oxygen and nutrients. Myocardial infarctions are typically caused by the blockage of a coronary artery by atherosclerotic plaque, a mass of cholesterol and white blood cells in the artery wall. OtiTopic has been working on the proprietary formulation since 2012 and is focused on bringing this therapy to market.


Get in touch with us for more info about OtiTopic, Inc.